Clinical Trial Update: Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating Hu3F8-BsAb for relapsed/refractory neuroblastoma and osteosarcoma terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma
• Osteosarcoma

Drugs mentioned

• Hu3F8-BsAb (humanized 3F8 bispecific antibody) (Hu3F8-BsAb)

Snippet

Sponsor: Y-mAbs Therapeutics | Conditions: Neuroblastoma, Osteosarcoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-06-22